BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The spotlight continues to shine on lipid nanoparticles as the
  'go-to' delivery vehicle\, however the demand remains to translate learn
 ings from vaccine LNP-mRNA success into therapeutic applications. Positio
 ned as a delivery vehicle with no ceiling to innovation\, drug developers
  across the field are continuing to progress research to target the previ
 ously unreachable and treating the undruggable. Pinpoint the lipid compon
 ents and structural complexities\, advance formulative strategy and strea
 mline manufacture to revolutionise your LNP design.\n\nThe 3rd Lipid Nano
 particles Development Summit Europe is your premier forum to collaborate 
 with a carefully curated community of experts across Discovery\, Characte
 risation\, Translatability\, Formulation\, Biodistribution\, Manufacturin
 g and much more. These industry leaders are gathering in Berlin this Sept
 ember to bring the greatest challenges in LNP development to the fore\, t
 ackling them head on to ensure 2024 is the year of the LNP.\n\nJoin us th
 is September address your unanswered questions and drive your development
  of LNPs to the next level\, supercharging innovation in your approach to
  safe\, stable and targeted drug delivery.\n\nURLs:Tickets: https://go.ev
 vnt.com/2504387-1?pid=185Brochure: https://go.evvnt.com/2504387-3?pid=185
 \n\nTime: 8:30 AM - 4:00 PM\n\nSpeakers: Alexander Kros\, Professor\, Lei
 den University\, Christian Plank\, Chief Technology Officer\, Ethris\, Da
 niel Tondera\, Head of Biology\, Pantherna Therapeutics\, Dimitrios Lampr
 ou\, Professor\, Queen's University Belfast\, Emily Young\, Non-Viral For
 mulation Lead\, 4basebio\, Jens Bæk Simonsen\, Independent Scientific Con
 sultant\, Jbsimonsen Consult\, Jeremie Parot\, Research Scientist\, SINTE
 F\, Joanna Grudzinska-Goebel\, DMPK Project Lead/ Immunogenicity Expert\,
  Bayer AG\, Kinkini Roy\, Associate Director\, Aviceda Therapeutics\, Lau
 ra Breda\, Scientific Co-Director Children’s Hospital of Philadelphia\, R
 oland Bottger\, Senior Research Scientist\, CureVac\, Selma Pereira Lopes
 \, Head of Drug Product Development Leiden\, Johnson and Johnson Innovati
 ve Medicine\, Sandipan Dawn\, Principal Scientist\, Ocular Therapeutix\, 
 Laurent Strodiot\, Director\, R and D\, GSK\, Rongjun Chen\, Professor Im
 perial College\, London\, Robert Worsham\, Senior Director\, Manufacturin
 g Science and Technology\, Insmed\, Martino Alfredo\, Cappelluiti Post-Do
 ctoral Researcher\, San Raffaele Telethon Institute for Gene Therapy\, Mo
 stafa Nakach\, Global Head of Process Engineering for Biologic Drug Produ
 ct Development\, Sanofi\, Neill Liptrott\, Professor of Pharmacology and 
 Immunocompatibility\, University of Liverpool\, Richard Campbell\, Senior
  Lecturer\, University of Manchester\n
DTEND:20240926T160000
DTSTAMP:20260512T231936Z
DTSTART:20240924T083000
LOCATION:Meliá Berlin\, 103\, Friedrichstraße\, Berlin\, Berlin\, 10117\,
SEQUENCE:0
SUMMARY:The spotlight continues to shine on lipid nanoparticles as the 'go
 -to' delivery vehicle\, however the demand remains to translate learnings
  from vac...
UID:00bdf01c-3a29-4557-9e56-8f83c1b23958
END:VEVENT
END:VCALENDAR